On June 23, 2025, Novo Nordisk announced it would halt its collaboration with Hims & Hers Health, stating that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy. This decision came less than two months after the partnership was initially announced.
Novo Nordisk cited concerns over Hims & Hers Health's promotion and sale of compounded versions of GLP-1 weight-loss drugs, emphasizing patient safety and the dangers of illicit active pharmaceutical ingredients. This termination underscores Novo Nordisk's aggressive stance against unlawful compounding.
While protecting the integrity of its branded products, this move means the loss of a distribution channel for Wegovy through a telehealth platform. It reflects Novo Nordisk's commitment to ensuring patients receive authentic, FDA-approved medications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.